Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Auxilium Pharmaceuticals, Inc.    AUXL

No quotes available
-- USD   0.00%
2015 EXCLUSIVE : Drugmaker Endo vying for Salix takeover
2015 AUXILIUM PHARMA : Announces Results from Special Meeting of Stockhol..
2015DJEndo International to Join S&P 500 as Boston Beer Moves Up to Mid..
SummaryQuotesNewsCompany 
News SummaryMost relevantAll newsSector news 

Auxilium Pharmaceuticals, Inc. : to Present at the Leerink Swann Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2013 | 01:50pm CEST

CHESTERBROOK, Pa., Feb. 12, 2013 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Leerink Swann Global Healthcare Conference to be held February 13-14, 2013 at the Waldorf Astoria Hotel in New York City. Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 2:30 p.m. ET on Thursday, February 14, 2013.

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )

The presentation will also be webcast on the "For Investors" section of the Auxilium website under the "Events" tab on February 14, 2013. To access the live webcast, please log on to Auxilium's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software. The presentation replay will be available for ninety days after the event.

About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical treatment of hypogonadism and XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord in the U.S. GSK co-promotes Testim with Auxilium in the U.S. Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada. Pfizer has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46 countries in Eurasia through April 24, 2013; Asahi Kasei Pharma Corporation has development and commercial rights for XIAFLEX in Japan; and Actelion Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in Canada, Australia, Brazil and Mexico. The sBLA for XIAFLEX for the treatment of Peyronie's disease was submitted to the FDA in November 2012. Additionally, collagenase clostridium histolyticum ("CCH") is in phase IIa of development for the treatment of Frozen Shoulder syndrome (adhesive capsulitis) and phase Ib of development for the treatment of cellulite (edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue additional indications for CCH. For additional information, visit http://www.auxilium.com

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995, including statements made with respect to Auxilium's strategy, progress and timing of development programs and related trials, the efficacy of its product candidates, the commercial benefits available to it as a result of its agreements with third parties, future operations, financial position, future revenues, projected costs, prospects, plans and objectives of management and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Although forward-looking statements are based on Auxilium's current plans or assessments that are believed to be reasonable as of the date of this press release, they inherently involve certain risks and uncertainties. These forward-looking statements are subject to a number of risks and uncertainties, including those discussed under ''Risk Factors'' in Auxilium's Annual Report on Form 10-K for the year ended December 31, 2011, each of Auxilium's Quarterly Reports on Form 10-Q for the three months ended September 30, 2012, June 30, 2012 and March 31, 2012 and Auxilium's preliminary prospectus supplement and Current Report on Form 8-K, each filed with the Securities and Exchange Commission (the "SEC") on January 23, 2013. While Auxilium may elect to update the forward-looking statements made in this news release in the future, Auxilium specifically disclaims any obligation to do so. Auxilium's SEC filings may be accessed electronically by means of the SEC's home page on the Internet at http://www.sec.gov. There may be additional risks that Auxilium does not presently know or that Auxilium currently believes are immaterial which could also cause actual results to differ from those contained in the forward-looking statements.

For More Information, Contact:

Contacts:
James E. Fickenscher/CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
jfickenscher@auxilium.com

William Q. Sargent Jr./ VP IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
wsargent@auxilium.com

SOURCE Auxilium Pharmaceuticals, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AUXILIUM PHARMACEUTICALS,
2015 EXCLUSIVE : Drugmaker Endo vying for Salix takeover
2015 AUXILIUM PHARMACEUTICALS : Announces Results from Special Meeting of Stockholder..
2015DJEndo International to Join S&P 500 as Boston Beer Moves Up to MidCap List
2014 AUXILIUM PHARMACEUTICALS : Sobi's Xiapex receives positive opinion by CHMP for t..
2014 AUXILIUM PHARMACEUTICALS : Announces Date for Special Meeting of Stockholders
2014 AUXILIUM PHARMACEUTICALS : Presents XIAFLEX For Peyronie's Disease Data At SMSNA..
2014 AUXILIUM PHARMACEUTICALS : Presents STENDRA Data At SMSNA Scientific Meeting
2014 AUXILIUM PHARMACEUTICALS : Endo Announces Early Termination of HSR Act Waiting P..
2014 AUXILIUM PHARMACEUTICALS : Endo Announces Early Termination of HSR Act Waiting P..
2014 AUXILIUM PHARMACEUTICALS : to Present XIAFLEX and STENDRA Data at SMSNA Scientif..
More news
Sector news : Biopharmaceuticals
06:16pDJFertilizer Producers Agrium and Potash in Merger Talks
04:01pDJOrexigen in Canadian Marketing Pact With Valeant for Diet Drug
08:49aDJBusiness Watch -- WSJ
08/29 Mylan to launch generic EpiPen at half the price of original
08/29DJMondelez Walks Away After Hershey Spurns Raised Bid
More sector news : Biopharmaceuticals
News from SeekingAlpha
2015 Vivus' Stendra To Get A Re-Launch
2015 FDA imposes limits on testosterone drugs and labeling changes to warn of pote..
2015 WINNERS CIRCLE 2014 TOP HEDGE FUND M : Healthcare Funds, Nine Of Top Ten Spots